Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)
Publication
, Journal Article
Udelson, JE; Lewis, GD; Shah, SJ; Zile, MR; Redfield, MM; Burnett, J; Mittleman, RS; Profy, AT; Seferovic, JP; Reasner, D; Konstam, MA
Published in: American Heart Journal
April 2020
Duke Scholars
Published In
American Heart Journal
DOI
ISSN
0002-8703
Publication Date
April 2020
Volume
222
Start / End Page
183 / 190
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Udelson, J. E., Lewis, G. D., Shah, S. J., Zile, M. R., Redfield, M. M., Burnett, J., … Konstam, M. A. (2020). Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). American Heart Journal, 222, 183–190. https://doi.org/10.1016/j.ahj.2020.01.009
Udelson, James E., Gregory D. Lewis, Sanjiv J. Shah, Michael R. Zile, Margaret M. Redfield, John Burnett, Robert S. Mittleman, et al. “Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).” American Heart Journal 222 (April 2020): 183–90. https://doi.org/10.1016/j.ahj.2020.01.009.
Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J, et al. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). American Heart Journal. 2020 Apr;222:183–90.
Udelson, James E., et al. “Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).” American Heart Journal, vol. 222, Elsevier BV, Apr. 2020, pp. 183–90. Crossref, doi:10.1016/j.ahj.2020.01.009.
Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J, Mittleman RS, Profy AT, Seferovic JP, Reasner D, Konstam MA. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). American Heart Journal. Elsevier BV; 2020 Apr;222:183–190.
Published In
American Heart Journal
DOI
ISSN
0002-8703
Publication Date
April 2020
Volume
222
Start / End Page
183 / 190
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology